1. A composition comprising:! effective amount of vaccine adjuvant represented by the structure of formula 1:! ! or a pharmaceutically acceptable salt thereof； and a vaccinating agent. ! 2. The composition according to claim 1, where the vaccinating agent is selected from the group consisting of a killed microorganism, a live attenuated viral microorganism, a toxoid, a fragment of an inactivated or attenuated microorganism, DNA and a unique marker (eg protein, glycoprotein, saccharide) or a combination of markers on cancer cells or microorganisms. ! 3. The composition according to claim 1, where the subject is administered the composition by subcutaneous, intravenous, intranasal, intramuscular or oral routes. ! 4. The composition according to claim 1, where the composition shows a neutralizing effect against the H5N1 influenza virus. ! 5. The composition according to claim 4, where the H5N1 influenza virus is at least one of the wild-type H5N1 influenza virus (E319), TK05, VN1194, ID05 and Anhui05. ! 6. The composition according to claim 1, where the vaccinating agent is at least one of pCHA5 and pCHA5-II. ! 7. The composition according to claim 1, where the composition causes an increase in the production of at least one of the pro-inflammatory cytokines, T-helper cytokines of type I and II and chemokines involved in cell proliferation and chemotaxis. ! 8. The composition according to claim 1, where the composition is effective for increasing the expression of cytokines of at least one of IL-2, IL-5, IL-13, RANTES, MIP-1α, MIP-1β, KC, IL-1β, IL-17, IL-12p40, G-CSF and IFN-γ. ! 9. A pharmaceutical composition for use in antitumor immunotherapy, containing an effective amount of a compound represented by the structure of formula 1:! ! or a pharmaceutically acceptable salt thereof. ! 10. Pharmacists1. Композиция, содержащая: ! эффективное количество адъюванта вакцины, представленного структурой формулы 1: ! ! или его фармацевтически приемлемой соли； и вакцинирую
